Skip to main content
Kenneth Pienta, MD, Oncology, Baltimore, MD

KennethJPientaMD

Oncology Baltimore, MD

Genitourinary Oncology, Hematologic Oncology

Professor, Johns Hopkins University

Dr. Pienta is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Pienta's full profile

Already have an account?

  • Office

    600 N Wolfe St
    Oncology 123
    Baltimore, MD 21287
    Phone+1 410-283-1016

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1988 - 1991
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 1986 - 1988
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1986

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1987 - Present
  • MD State Medical License
    MD State Medical License 1988 - 2025
  • MI State Medical License
    MI State Medical License 1991 - 2025
  • IL State Medical License
    IL State Medical License 1986 - 1989
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2006-2020
  • America's Top Doctors for Cancer Castle Connolly, 2005-2020
  • Top Doctors:Baltimore Area Castle Connolly, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer  
    Emmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
  • Prostate-Specific Markers to Identify Rare Prostate Cancer Cells in Liquid Biopsies  
    Kenneth Pienta, MD, Nature
  • Cooperation Among Cancer Cells: Applying Game Theory to Cancer  
    Kenneth Pienta, MD, Nature
  • Join now to see all

Press Mentions

  • The Prostate Cancer Foundation Announces 2020 Challenge Awards Totaling More Than $11 Million for Prostate Cancer Research
    The Prostate Cancer Foundation Announces 2020 Challenge Awards Totaling More Than $11 Million for Prostate Cancer ResearchDecember 31st, 2020
  • A Prostate Cancer Community: Driving Access to Resources for Patients and Providers of Care - Felix Feng and Charles Ryan
    A Prostate Cancer Community: Driving Access to Resources for Patients and Providers of Care - Felix Feng and Charles RyanSeptember 24th, 2020
  • Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem Engineers
    Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem EngineersMarch 4th, 2020
  • Join now to see all

Grant Support

  • Prostate Cancer Induces CCL2 Expression And Transforms The Bone MicroenviNational Cancer Institute2009–2012
  • Mechanisms Of Prostate Cancer Dormancy In The Bone Marrow NicheNational Cancer Institute2011
  • Reactive Stroma And Tumor Associated Macrophages In Prostate Cancer ProgressionNational Cancer Institute2010–2011
  • Carryover From Year -09 For Phase II Evaluation Of EMD 12194National Cancer Institute2008–2011
  • Administration CoreNational Cancer Institute2008–2011
  • Spore In Prostate CancerNational Cancer Institute1995–2011
  • Annual Meeting For The Clinical Research Ethics Key Function CommitteeNational Center For Research Resources2010
  • CTSA Infrastructure For Pediatric ResearchNational Center For Research Resources2009–2010
  • CTSA Infrastructure For Clinical TrialsNational Center For Research Resources2009–2010
  • CTSA Infrastructure For AIDS ResearchNational Center For Research Resources2009–2010
  • Michigan Institute For Clinical And Health Research (MICHR) (UL1)National Center For Research Resources2008–2010
  • Michigan Institute For Clinical And Health Research (MICHR) (Ul1): (BPCA)National Center For Research Resources2009
  • Michigan Institute For Clinical And Health Research (MICHR) (TL1)National Center For Research Resources2008–2009
  • Michigan Institute For Clinical And Health Research (MICHR) (KL2)National Center For Research Resources2008–2009
  • The Therapeutic Potential, Pharmacology And Toxiciity Of Promising Small-MoleculeNational Cancer Institute2005–2009
  • PAR1 In Prostate Cancer Cell Motility And InvasionNational Cancer Institute2004–2008
  • S.P.O.R.E. In Prostate CancerNational Cancer Institute2003–2007
  • Molecular Changes Associated With PCA Bone MetastasesNational Cancer Institute2003–2006
  • Urology Research Training GrantNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2004
  • Pilot--Prostate Cancer And Urological OncologyNational Cancer Institute2001–2002
  • Inhibition Of Human Prostate Cancer MetastasisNational Cancer Institute1998–2002
  • Developmental Research ProgramNational Cancer Institute1998–2002
  • Prostate Cancer Metastasis To BoneNational Cancer Institute1999–2000
  • Nuclear Matrix As A Target For Prostate Cancer ChemotherapyNational Center For Research Resources1998–1999
  • Phase II Clinical Trials Of New Chemopreventive AgentsDivision Of Cancer Prevention And Control1998
  • Aminocamptothecin (9 Ac/Dma) In Hormone Refractory Prostate CancerNational Center For Research Resources1997
  • Inhibition Of Human Prostate-Cancer Metastasis By Modified Citrus PectinNational Cancer Institute1996–1997
  • Emcyt, VP16, And Taxol For Metastatic Prostate CancerNational Cancer Institute1996–1997
  • Organization Of DNA In Cancer CellsNational Cancer Institute1994–1996
  • Nuclear Matrix As A Cancer Chemotherapy TargetNational Cancer Institute1994
  • The Organization Of DNA In Cancer CellsNational Cancer Institute1993
  • Nuclear Matrix As A Cancer Chemotherapy TargetNational Cancer Institute1992–1993
  • Organization Of DNA In Cancer CellsNational Cancer Institute1992

Professional Memberships